Skip to main content
WHO Solidarity trial medRxiv
17, Oct 2020

WHO Solidarity Trial of Repurposed Antiviral Drugs in COVID-19 Reports Little to No Effect

WHO Solidarity Trial of Repurposed Antiviral Drugs in COVID-19 Reports Little to No Effect on Mortality, Severity, and Length of Hospital Stay.

11,266 adult patients with COVID-19 were enrolled in 405 hospitals in 30 countries. Patients were randomized equally to receive any one of the four locally available drug regimens, Remdesivir, Hydroxychloroquine, Lopinavir or Interferon beta-1a and no antiviral.

1,253 deaths occurred at a median 8 days after enrollment. No study drug reduced deaths, progression to ventilation for respiratory failure, or length of hospitalization.

  • These results are consistent with meta-analysis of mortality in all major trials.
  • The study was supported by the World Health Organization (NCT04315948).
  • Study results have not undergone peer-review.

Source: Pre-print server medRxiv (ISRCTN83971151), not certified by peer-review.

About

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to

  • - Assess disease risk for several immunological disorders.
  • - Predict the success of a drug for a specific patient.
  • - Develop dosing recommendations for new immunological drugs.

Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.

Contact